Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY26 results · Jan–Mar 2026
Procter & Gamble Health reported revenue from operations of ₹370.45 crore and net profit of ₹94.60 crore for Q4 FY26 (Jan–Mar 2026), on a standalone basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 370.45 | — | — | 373.86 | −0.9% |
| Other income | 4.00 | — | — | 4.36 | −8.3% |
| Total income | 374.45 | — | — | 378.22 | −1.0% |
| Profit before tax | 133.21 | — | — | 108.82 | +22.4% |
| Net profit for the period | 94.60 | — | — | 77.59 | +21.9% |
| EPS, basic (₹) | 56.99 | — | — | 46.74 | +21.9% |
| Net margin (%) | 25.5 | — | 20.8 |
Standalone
- Filed with BSE
- 27 May 2026, 15:21 IST
- Board meeting
- 26 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE